Preferences of Adult Patients With Inflammatory Bowel Disease for Attributes of Clinical Trials: Evidence From a Choice-Based Conjoint Analysis

被引:6
作者
Wood, Dallas [1 ]
Kosa, Katherine [1 ]
Brown, Derek [2 ]
Ehrlich, Orna G. [3 ]
Higgins, Peter D. R. [4 ]
Heller, Caren [3 ]
机构
[1] RTI Int, Res Triangle Pk, NC USA
[2] Washington Univ, George Warren Brown Sch Social Work, St Louis, MO 63110 USA
[3] Crohns & Colitis Fdn, New York, NY USA
[4] Univ Michigan, Ann Arbor, MI 48109 USA
关键词
inflammatory bowel disease; ulcerative colitis; Crohn's disease; clinical trials; conjoint analysis; patient recruitment; PARTICIPATION; DESIGN;
D O I
10.1093/crocol/otz048
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Clinical trial recruitment is the rate-limiting step in developing new treatments. To understand inflammatory bowel disease (IBD) patient recruitment, we investigated two questions: Do changes in clinical trial attributes, like monetary compensation, influence recruitment rates, and does this influence differ across subgroups? Methods: We answered these questions through a conjoint survey of 949 adult IBD patients. Results: Recruitment rates are influenced by trial attributes: small but significant increases are predicted with lower placebo rates, reduced number of endoscopies, less time commitment, open label extension, and increased involvement of participant's primary GI physician. A much stronger effect was found with increased monetary compensation. Latent class analysis indicated three patient subgroups: some patients quite willing to participate in IBD trials, some quite reluctant, and others who can be persuaded. The persuadable group is quite sensitive to monetary compensation, and payments up to US$2,000 for a 1-year study could significantly increase recruitment rates for IBD clinical trials. Conclusions: This innovative study provides researchers with a framework for predicting recruitment rates for different IBD clinical trials.
引用
收藏
页数:16
相关论文
共 20 条
[1]   Insights and Best Practices for Planning and Implementing Patient Advisory Boards [J].
Anderson, Annick ;
Getz, Kenneth A. .
THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2018, 52 (04) :469-473
[2]  
[Anonymous], 2019, STATA VERSION 15 0
[3]  
[Anonymous], 2010, Sawtooth Software SSI Web 7.0.10
[4]  
[Anonymous], 2009, LOS ANGELES TIMES
[5]   Factors determining participation in prevention trials among systemic lupus erythematosus patients: A qualitative study [J].
Costenbader, Karen H. ;
Brome, Deborah ;
Blanch, Danielle ;
Gall, Victoria ;
Karlson, Elizabeth ;
Liang, Matthew H. .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2007, 57 (01) :49-55
[6]   Prevalence of Inflammatory Bowel Disease Among Adults Aged ≥18 Years - United States, 2015 [J].
Dahlhamer, James M. ;
Zammitti, Emily P. ;
Ward, Brian W. ;
Wheaton, Anne G. ;
Croft, Janet B. .
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2016, 65 (42) :1166-1169
[7]  
Ehrlich O, 2018, 19000273 MEDRXIV
[8]  
Getz KA, 2012, APPL CLIN TRIALS, V21
[9]   Payment of clinical research subjects [J].
Grady, C .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (07) :1681-1687
[10]   Crohn's disease patients' risk-benefit preferences:: Serious adverse event risks versus treatment efficacy [J].
Johnson, F. Reed ;
Oezdemir, Semra ;
Mansfield, Carol ;
Hass, Steven ;
Miller, David W. ;
Siegel, Corey A. ;
Sands, Bruce E. .
GASTROENTEROLOGY, 2007, 133 (03) :769-779